Brief: Moberg Pharma Receives Favorable Outcome From NAD
Jan 15 (Reuters) - Moberg Pharma Ab (Publ) MBPH.ST :
* MOBERG PHARMA RECEIVES FAVORABLE OUTCOME FROM NAD - MAIN
COMPETITOR TO DISCONTINUE CURRENT MARKETING
* EXPECTS OUTCOME TO FURTHER STRENGTHEN KERASAL NAILS
POSITION
AND GROWTH PROSPECTS IN U.S. MARKET
Source text for Eikon: ID:nWkrfqqbY
Further company coverage: MBPH.ST
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 587720920;))
Recent news on Moberg Pharma AB (publ)
See all newsSweden's Moberg Pharma Q2 loss narrows as revenue rises
Brief: Moberg Pharma Q2 EBITDA SEK -4.3 Million
Brief: Moberg Pharma Names Vaidrius Navikas Chief Medical Officer
Brief: Moberg Pharma And Karo Healthcare Expand Collaboration
Moberg Pharma Q1 revenue rises, losses narrow on Nordic market share gains